Your browser is no longer supported. Please, upgrade your browser.
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Basic TA News Snapshot Stats
Total: 46 #1
CompanyFluidigm Corporation
IndustryMedical Laboratories & Research
Market Cap353.40MEPS (ttm)-1.37
P/E-EPS this Y18.90%
Forward P/E-EPS next Y32.30%
PEG-EPS past 5Y-18.10%
P/S2.95EPS next 5Y-8.06%
P/B2.04EPS Q/Q52.20%
Dividend-Sales Q/Q6.80%
Insider Own0.70%Inst Own96.50%
Insider Trans-80.95%Inst Trans0.51%
Short Float2.34%EarningsNov 05/a
Analyst Recom1.80Target Price10.70
Avg Volume741.54K52W Range4.03 - 14.90
Nov-06-19Downgrade Janney Buy → Neutral
Nov-06-19 02:08AMEdited Transcript of FLDM earnings conference call or presentation 5-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-05-19 07:55PMFluidigm (FLDM) Reports Q3 Loss, Misses Revenue Estimates Zacks
Nov-05-19 04:05PMFluidigm Announces Third Quarter 2019 Financial Results GlobeNewswire
Nov-05-19 04:02PMFluidigm Drives a New Standard in Human Immune Profiling GlobeNewswire
Nov-01-19 08:17AMEstimating The Fair Value Of Fluidigm Corporation (NASDAQ:FLDM) Simply Wall St.
Oct-29-19 10:33AMFluidigm (FLDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Oct-28-19 08:23PMFluidigm Corporation (FLDM) Is Burning These Hedge Funds Insider Monkey
Oct-15-19 04:15PMFluidigm Showcases RNA Sequencing Innovations Using Microfluidics Technology at the 2019 American Society of Human Genetics (ASHG) Meeting GlobeNewswire
Oct-10-19 04:10PMFluidigm Announces Conference Call and Webcast of Third Quarter 2019 Financial Results GlobeNewswire
Sep-26-19 09:16AMDoes Fluidigm Corporation's (NASDAQ:FLDM) CEO Salary Compare Well With Others? Simply Wall St.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments and consumables, including IFCs, assays, and reagents to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. The company sells its products to academic institutions, life sciences, and clinical research laboratories that conduct research, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Levin Easterly Partners LLCPassive InvestorSep 17Sale5.40577,1973,116,8646,909,871Sep 19 04:27 PM
Levin Easterly Partners LLCPassive InvestorSep 11Sale5.5511,54564,1127,487,068Sep 13 04:22 PM
COLELLA SAMUEL DDirectorAug 27Buy5.192,00010,372119,481Aug 28 09:13 PM
Linthwaite Stephen ChristopherPresident & CEOAug 23Buy5.524,00022,077171,391Aug 27 07:58 PM
Khadder NicholasSee RemarksAug 20Option Exercise0.004,901042,962Aug 22 05:54 PM
CompanySupernus Pharmaceuticals, Inc.
IndustryDrugs - Generic
Market Cap1.53BEPS (ttm)1.94
P/E15.00EPS this Y63.20%
Forward P/E14.73EPS next Y-9.60%
PEG0.41EPS past 5Y22.00%
P/S3.73EPS next 5Y37.00%
P/B2.92EPS Q/Q7.00%
Dividend-Sales Q/Q5.20%
Insider Own1.10%Inst Own98.94%
Insider Trans1.27%Inst Trans-0.46%
Short Float12.33%EarningsNov 05/a
Analyst Recom1.70Target Price50.83
Avg Volume564.35K52W Range24.77 - 49.25
Nov-06-19Downgrade Jefferies Buy → Hold $46 → $23
Nov-05-19 06:45PMSupernus Pharmaceuticals (SUPN) Q3 Earnings and Revenues Lag Estimates Zacks
Nov-05-19 04:55PMSupernus Announces Third Quarter 2019 Financial Results and Topline Data from Phase III Study of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients GlobeNewswire
Oct-29-19 10:32AMSupernus Pharmaceuticals (SUPN) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Oct-28-19 08:53AMWere Hedge Funds Right About Dumping Supernus Pharmaceuticals Inc (SUPN)? Insider Monkey
Oct-24-19 04:10PMSupernus to Host Third Quarter 2019 Earnings Conference Call GlobeNewswire
Oct-22-19 03:49PMEstimating The Fair Value Of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Simply Wall St.
Oct-02-19 01:04PMSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Insiders Increased Their Holdings Simply Wall St.
Sep-25-19 02:21PMSupernus to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire
Sep-13-19 01:54PM5 Health Care Stocks Gurus Are Buying
Sep-02-19 09:50AMHow Does Investing In Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Impact The Volatility Of Your Portfolio? Simply Wall St.
Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. The company's product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with ADHD; SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine for bipolar; and SPN-817 that is in phase I clinical trial for treating epilepsy. The company markets its products through wholesalers and distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Khattar Jack A.President, CEOAug 23Buy26.397,200189,982465,141Aug 27 05:27 PM
SIEBERT JOHN MDirectorJun 20Option Exercise9.1310,00091,30055,742Jun 24 08:06 PM
SIEBERT JOHN MDirectorApr 25Option Exercise9.1310,00091,30045,742Apr 29 03:43 PM
PATRICK GREGORY SSr VP, Chief Financial OfficerFeb 27Option Exercise9.1320,000182,60067,896Feb 28 04:29 PM
PATRICK GREGORY SSr VP, Chief Financial OfficerFeb 27Sale41.5320,000830,65047,896Feb 28 04:29 PM
CompanyCyclerion Therapeutics, Inc.
Market Cap61.48MEPS (ttm)-4.74
P/E-EPS this Y-22.70%
Forward P/E-EPS next Y60.50%
PEG-EPS past 5Y-
P/S38.42EPS next 5Y-
P/B0.45EPS Q/Q41.40%
Dividend-Sales Q/Q-
Insider Own0.80%Inst Own73.50%
Insider Trans-Inst Trans0.20%
Short Float4.48%Earnings-
Analyst Recom3.00Target Price5.00
Avg Volume295.37K52W Range2.27 - 22.85
Nov-01-19 10:52AMIronwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View Zacks
Oct-31-19 08:08AMThe Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut Benzinga
Oct-30-19 09:24AMCyclerion's stock plummets to pace premarket losers after diabetes treatment study missed primary endpoint MarketWatch
Oct-30-19 08:17AMIronwood spinout Cyclerion plans 30 layoffs after drug fails mid-stage trial American City Business Journals
Oct-30-19 07:31AMCyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results in Diabetic Nephropathy GlobeNewswire
Oct-30-19 07:30AMCyclerion Therapeutics Announces Topline Phase 2 Results for sGC Stimulator Praliciguat in Heart Failure with Preserved Ejection Fraction (HFpEF) GlobeNewswire
Oct-08-19 08:00AMCyclerion Therapeutics and Collaborators to Present New Research on the Sickle Cell Disease Patient Journey at Upcoming Medical Meetings GlobeNewswire
Sep-25-19 01:22PMRead This Before Selling Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares Simply Wall St.
Sep-10-19 08:00AMCyclerion to Host Webcast Investor Event on Cardiometabolic Programs on September 17 GlobeNewswire
Aug-12-19 08:00AMCyclerion Therapeutics Reports Second Quarter 2019 Financial Results and Progress on Four Clinical Studies with Data Readouts Anticipated in the Next 12 Months GlobeNewswire
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its lead product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of serious cardiometabolic diseases, such as diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for serious and orphan central nervous system diseases. The company's products that are in discovery stage include liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is based in Cambridge, Massachusetts.
CompanySierra Wireless, Inc.
IndustryCommunication Equipment
Market Cap407.84MEPS (ttm)-1.23
P/E-EPS this Y-597.50%
Forward P/E14.44EPS next Y144.06%
PEG-EPS past 5Y-6.20%
P/S0.53EPS next 5Y12.00%
P/B1.00EPS Q/Q-146.60%
Dividend-Sales Q/Q-5.20%
Insider Own6.60%Inst Own44.40%
Insider Trans0.00%Inst Trans0.14%
Short Float2.17%EarningsNov 05/a
Analyst Recom2.70Target Price15.30
Avg Volume179.20K52W Range10.04 - 19.81
Nov-06-19Downgrade Raymond James Outperform → Mkt Perform
Nov-05-19 07:35PMSierra Wireless (SWIR) Lags Q3 Earnings and Revenue Estimates Zacks
Nov-05-19 05:21PMSierra Wireless stock heads toward lowest price since 2016 after earnings forecast cut MarketWatch
Nov-05-19 04:32PMSierra Wireless Reports Third Quarter 2019 Results Business Wire
Nov-01-19 12:07PMWere Hedge Funds Right About Dumping Sierra Wireless, Inc. (SWIR)? Insider Monkey
Oct-29-19 10:33AMAnalysts Estimate Sierra Wireless (SWIR) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-28-19 08:30AMSierra Wireless to Report Third Quarter 2019 Results on November 5th Business Wire
Oct-24-19 08:00AMSierra Wireless Delivers Advanced Offender Monitoring Solution With LTE Connectivity and Voice Commands Business Wire
Oct-17-19 08:00AMSierra Wireless Octave Now Available, Unlocking Data from Millions of Industrial Assets Business Wire
Sep-10-19 09:00AMSierra Wireless Appoints Lori ONeill to Board of Directors Business Wire
Aug-01-19 03:30PMSierra Wireless Lays the Foundation for Return to Growth Motley Fool
Sierra Wireless, Inc., together with its subsidiaries, manufactures and sells cellular wireless devices, and provide services in the wireless communications and information technology industry in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. Its Original Equipment Manufacturer (OEM) Solutions segment offers embedded cellular modules, short range wireless modules, global navigation satellite system modules, software, and tools to integrate wireless connectivity into various products and solutions for OEM customers, including the embedded wireless modules product portfolio; cloud-based remote device and data management solutions; and Legato, an open source Linux-based platform. It also offers professional services to OEM customers during their product development and launch process. Its Enterprise Solutions segment provides intelligent routers and gateways, as well as security and device management solutions, and professional services. Its Internet of Things (IoT) Services segment offers cellular connectivity services, which include smart subscriber identity module and core network platforms; a cloud based platform to deploy and manage IoT subscriptions, devices, and applications over the air; managed broadband cellular services, which include a combination of hardware, connectivity services, and cloud services; and specific vertical market IoT solutions that include segments, such as security, asset tracking and asset optimization. The company serves automotive, transportation, enterprise networking, energy, sales and payment, mobile computing, security, industrial monitoring, field services, residential, healthcare, public safety, retail, industrial, manufacturing, and cleantech industries, as well as financial enterprises. It serves through direct channels; and indirect channels, including OEMs, distributors, value-added resellers, and mobile network operators. The company was founded in 1993 and is headquartered in Richmond, Canada.
CompanyCHF Solutions, Inc.
IndustryMedical Appliances & Equipment
Market Cap2.16MEPS (ttm)-24.68
P/E-EPS this Y92.00%
Forward P/E-EPS next Y42.90%
PEG-EPS past 5Y-
P/S0.37EPS next 5Y-
P/B0.24EPS Q/Q85.20%
Dividend-Sales Q/Q54.50%
Insider Own1.99%Inst Own11.60%
Insider Trans0.00%Inst Trans-2.36%
Short Float-EarningsNov 05/b
Analyst Recom1.00Target Price15.00
Avg Volume715.10K52W Range0.82 - 18.90
Nov-05-19 08:00AMCHF Solutions, Inc. Announces Third Quarter Financial Results and Provides Company Update GlobeNewswire
Nov-04-19 09:19AMCHF Solutions, Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market GlobeNewswire
Nov-01-19 08:00AMCHF Solutions, Inc. Announces Sales Force Realignment To Increase Focus On Cardiac Surgery And Eventually Pediatrics GlobeNewswire
Oct-31-19 04:17PMPenny Stocks to Buy Using Technical Analysis for November 2019 Investopedia
Oct-29-19 08:00AMCHF Solutions, Inc. To Announce Third Quarter 2019 Financial Results and Corporate Update on November 5, 2019 GlobeNewswire
Oct-24-19 08:00AMAbington Hospital Begins a 344 Patient Retrospective Clinical Study to Analyze Experience with CHF Solutions Aquadex FlexFlow® System GlobeNewswire
Oct-23-19 09:10AMCHF Solutions, Inc. Announces Pricing of Registered Direct Offering GlobeNewswire
Oct-17-19 08:30AMCHF Solutions to Exhibit at The American College of Chest Physicians (CHEST) Annual Meeting 2019 GlobeNewswire
Oct-15-19 08:00AMMicroCap Rodeo Investor Conference Lineup for October 15 and 16, 2019 ACCESSWIRE
Oct-14-19 09:35AMCHF Solutions System to be Used in JAHVH Study After Final Nod Zacks
CHF Solutions, Inc., a medical device company, focuses on the provision of solutions for patients suffering from fluid overload. The company's commercial product is the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. Its Aquadex FlexFlow system includes a console, and disposable blood set and catheter. The company sells its products to hospitals and clinics through its direct Salesforce in the United States; and through independent specialty distributors primarily in Brazil, Germany, Hong Kong, India, Italy, Singapore, Spain, Thailand, and the United Kingdom. The company was formerly known as Sunshine Heart, Inc. and changed its name to CHF Solutions, Inc. in May 2017. CHF Solutions, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ERB JOHN LCEO and PresidentMar 12Buy5.259,52349,99611,615Mar 12 04:40 PM
CompanyUber Technologies, Inc.
IndustryApplication Software
Market Cap47.83BEPS (ttm)-3.01
P/E-EPS this Y100.00%
Forward P/E-EPS next Y57.70%
PEG-EPS past 5Y-
P/S3.93EPS next 5Y-
P/B1.95EPS Q/Q-803.40%
Dividend-Sales Q/Q12.90%
Insider Own10.80%Inst Own54.20%
Insider Trans-Inst Trans0.06%
Short Float4.11%EarningsNov 04/a
Analyst Recom2.20Target Price48.73
Avg Volume11.32M52W Range27.97 - 47.08
Nov-06-19 10:26AMU.S. Equities Fluctuate; Treasuries Rebound: Markets Wrap Bloomberg
Nov-06-19 10:06AMUber stock stumbles after lockup expiration MarketWatch
Nov-06-19 09:59AMUber shares fall to record low as stock lock-up expires Reuters
Nov-06-19 09:48AMUber Sinks to New Record Low as IPO Share Lockup Expires Bloomberg
Nov-06-19 09:46AMSoftBanks Son Defiant as WeWork Triggers $6.5 Billion Loss Bloomberg
Nov-06-19 09:30AMThe Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PUMP, MGNX, TME and UBER GlobeNewswire
Nov-06-19 09:26AMUber Stock Hit a Record Low, and More People Are Allowed to Sell Today
Nov-06-19 08:48AMRide-hailing market revs up in Egypt Reuters
Nov-06-19 08:38AMCan Uber Turn Things Around After Its Post-Earnings Sell-Off? TipRanks
Nov-06-19 05:06AM[video]Uber Backs Up to Record Low as Lockup Period Expires
Uber Technologies, Inc. develops and supports proprietary technology applications that enable independent providers of ridesharing, and meal preparation and delivery services to transact with end-users worldwide. The company operates in two segments, Core Platform and Other Bets. Its driver partners provide ridesharing services through a range of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis, as well as based on the number of riders under the UberBLACK, UberX, UberPOOL, Express POOL, and Uber Bus names; and restaurant and delivery partners provide meal preparation and delivery services under the Uber Eats name. The company also offers Uber Central, a tool that enables companies to request, manage, and pay for rides for their employees, customers, or partners; and Uber Health, which allows healthcare professionals to arrange rides for patients going to and from the care destinations. In addition, it provides freight transportation services to shippers in the freight industry under the Uber Freight name; leases vehicles to third-parties that use the vehicles to provide ridesharing or eats services through the platforms; and provides access to rides through personal mobility products, including dockless e-bikes and e-scooters under the JUMP name. The company was formerly known as Ubercab, Inc. and changed its name to Uber Technologies, Inc. in February 2011. Uber Technologies, Inc. was founded in 2009 and is headquartered in San Francisco, California.
CompanySynchronoss Technologies, Inc.
IndustryApplication Software
Market Cap211.89MEPS (ttm)-5.69
P/E-EPS this Y-62.30%
Forward P/E-EPS next Y9.40%
PEG-EPS past 5Y-67.40%
P/S0.64EPS next 5Y10.00%
P/B1.31EPS Q/Q48.80%
Dividend-Sales Q/Q1.40%
Insider Own5.20%Inst Own48.40%
Insider Trans-Inst Trans-0.51%
Short Float19.79%EarningsNov 04/a
Analyst Recom2.00Target Price12.00
Avg Volume501.32K52W Range4.82 - 9.05
Nov-05-19 03:36AMEdited Transcript of SNCR earnings conference call or presentation 4-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-04-19 05:25PMSynchronoss (SNCR) Reports Q3 Loss, Lags Revenue Estimates Zacks
Nov-04-19 04:00PMSynchronoss Technologies Announces Third Quarter 2019 Results; Signs New U.S.-based Tier 1 Cloud Customer; And Provides Update on relationship with Sequential Technology International GlobeNewswire
Nov-04-19 08:30AMIndosat Ooredoo and Synchronoss partner for unified customer engagement and new digital economy ecosystem GlobeNewswire
Oct-31-19 02:45PMSynchronoss and WeAre8 Partner to Leverage RCS-Enabled Messaging to Transform the Consumer-Brand Relationship PR Newswire
Oct-31-19 08:30AMBritish American Tobacco Selects Synchronoss Digital Experience Platform to Speed Delivery of Highly Optimized Customer Journeys GlobeNewswire
Oct-30-19 08:30AMSynchronoss Financial Analytics platform selected by Rackspace to accurately validate expenses and invoices GlobeNewswire
Oct-28-19 10:32AMSynchronoss (SNCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Oct-11-19 09:26AM3 Under-the-Radar Tech Stocks With Over 30% Upside TipRanks
Oct-09-19 08:30AMSynchronoss Technologies, Inc. Announces Date of Third Quarter Financial Results GlobeNewswire
Synchronoss Technologies, Inc. provides cloud, digital, messaging, and Internet of Things (IoT) platforms, products, and solutions in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company's platforms, products, and solutions include digital experience management platform as a service, which includes digital journey creation and journey design products that use analytics that power digital advisor products for IT and business channel owners; and cloud sync, backup, storage, device set up, content transfer, and content engagement for user generated content. Its platforms, products, and solutions also comprise multi-channel messaging peer-to-peer communications and application-to-person commerce solutions; and IoT management technology for smart cities, smart buildings, automotive, and others. In addition, the company offers software development and customization services. Its products and platforms enable multiple converged communications, commerce and applications, and devices to deploy across a range of distribution channels, such as e-commerce, m-commerce, telesales, retail stores, and care and call centers, as well as self-service, indirect, and other outlets. The company markets and sells its services through direct sales force and strategic partners. It has an agreement with Arrow Electronics, Inc. to develop end-to-end IoT smart building solutions. Synchronoss Technologies, Inc. was founded in 2000 and is headquartered in Bridgewater, New Jersey.
TickerCEI [NYSE]
CompanyCamber Energy, Inc.
IndustryOil & Gas Drilling & Exploration
Market Cap3.91MEPS (ttm)3740.50
P/E0.00EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S3.26EPS next 5Y-
P/B0.01EPS Q/Q-
Dividend-Sales Q/Q-94.10%
Insider Own0.68%Inst Own0.10%
Insider Trans0.00%Inst Trans-
Short Float0.88%EarningsNov 15/b
Analyst Recom-Target Price1.00
Avg Volume397.10K52W Range2.43 - 6640.63
Oct-29-19 08:30AMCamber Energy, Inc. Announces Effectiveness of OneforFifty Reverse Stock Split ACCESSWIRE
Oct-24-19 04:25PMCamber Energy, Inc. Announces One-for-Fifty Reverse Stock Split ACCESSWIRE
Oct-21-19 08:45AMCamber Energy Lineal Star Subsidiary CEO Tim Connolly to Appear Live on "CEO Money", Monday at 4:30 PM CDT CEO Will Discuss Form 8-K/Audit Filed October 7, 2019, Lineal Star 2019 Turnaround and 2020 Growth Plans ACCESSWIRE
Oct-17-19 08:00AMLineal Merger Sets Stage for Increased Revenue, Stability, and Growth ACCESSWIRE
Oct-08-19 08:00AMCamber Energy Subsidiary Lineal Star Holdings Completes Purchase of 80% Ownership of Evercon Energy LLC in College Station, Texas ACCESSWIRE
Oct-02-19 08:00AMCamber Energy Sub Lineal Industries Regains Major Legacy Customer Lost by Prior Owner ACCESSWIRE
Sep-26-19 08:15AMCamber Energy Subsidiary Lineal Star Holdings Schedules October 1, 2019 Closing Date to Purchase Evercon Energy LLC in College Station, Texas ACCESSWIRE
Sep-16-19 08:00AMCamber Energy Sub Lineal Industries Completes $7.7 Million Pipeline Relocation Project on the Southern Beltway in Pittsburgh, PA. ACCESSWIRE
Sep-05-19 06:00PMCamber Energy Subsidiary Lineal Star Holdings Signs Non-Binding LOI to Purchase Evercon Energy LLC in College Station, Texas ACCESSWIRE
Sep-03-19 08:00AMCamber Energy Subsidiary Lineal Industries Completing Construction of Alternative Energy Landfill Waste Gas Gathering Line ACCESSWIRE
Camber Energy, Inc., an independent oil and gas company, engages in the acquisition, development, and sale of crude oil, natural gas, and natural gas liquids (NGL) in Texas and Oklahoma. The company holds interests in approximately 13,000 net acres of producing fields located primarily in the Hunton formation in Lincoln, Logan and Payne, and Okfuskee Counties, in central Oklahoma; the Cline shale and upper Wolfberry shale in Glasscock County, Texas; and Panhandle situated in Hutchinson County, Texas. It also owns 3,000 leasehold acres in Okfuskee County, Oklahoma, which includes 8 producing wells and 3 salt water disposal wells; and owns 555 net leasehold acres in Hutchinson County, Texas, which includes 48 gross non-producing well bores and 5 salt water disposal wells. As of March 31, 2019, its total estimated proved reserves were 203,406 million barrels of oil equivalent comprising 124,520 barrels of crude oil, 44,100 barrels of NGL reserves and 208,710 million cubic feet of natural gas reserves. The company was formerly known as Lucas Energy Inc. and changed its name to Camber Energy, Inc. in January 2017. Camber Energy, Inc. was incorporated in 2003 and is headquartered in Houston, Texas.
TickerPLT [NYSE]
CompanyPlantronics, Inc.
IndustryCommunication Equipment
Market Cap1.52BEPS (ttm)-5.05
P/E-EPS this Y-243.20%
Forward P/E6.13EPS next Y12.37%
PEG-EPS past 5Y-27.90%
P/S0.80EPS next 5Y15.00%
P/B2.31EPS Q/Q-362.40%
Dividend1.52%Sales Q/Q102.30%
Insider Own1.50%Inst Own98.76%
Insider Trans-0.75%Inst Trans1.50%
Short Float10.13%EarningsNov 05/a
Analyst Recom1.80Target Price63.80
Avg Volume446.16K52W Range26.09 - 62.97
Nov-06-19Downgrade Northland Capital Outperform → Market Perform $70 → $35
Nov-06-19 08:04AMPlantronics Stock Is Plunging on Weak Earnings and a Soft Outlook
Nov-06-19 04:08AMEdited Transcript of PLT earnings conference call or presentation 5-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-05-19 05:55PMPlantronics (PLT) Misses Q2 Earnings and Revenue Estimates Zacks
Nov-05-19 04:57PMPlantronics stock plunges more than 25% after earnings guidance slashed MarketWatch
Nov-05-19 04:05PMPoly Announces Second Quarter Fiscal Year 2020 Financial Results PR Newswire
Nov-04-19 09:00AMPoly Introduces Poly Studio X Series for Microsoft Teams at Microsoft Ignite 2019 PR Newswire
Oct-30-19 08:15AM8x8, Poly and ScanSource Announce Strategic Partnership to Deliver Communications Industrys First Comprehensive Move to Cloud Program Business Wire
Oct-29-19 10:33AMPlantronics (PLT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
Oct-26-19 12:35PMIs Plantronics, Inc. (PLT) A Good Stock To Buy? Insider Monkey
Oct-22-19 09:00AMPoly Announces Date of Second Quarter 2020 Earnings Release and Investor Day PR Newswire
Plantronics, Inc. designs, manufactures, and markets various integrated communications and collaborations solutions for corporate customers, small businesses, and individuals worldwide. Its principal product categories include enterprise headsets, which comprise corded and cordless communication headsets; consumer headsets, such as Bluetooth and corded products for mobile device applications, personal computer, and gaming; voice, video, and content sharing solutions that include Open SIP desktop and conference room phones, and video endpoints designed to work with a range of unified communication and collaboration, unified communication as a service, and video as a service environments, including RealPresence collaboration solutions of infrastructure to endpoints that allows people to connect and collaborate; and support services. The company sells its products through a sales team, as well as through value-added resellers, integrators, direct marketing resellers, service providers, resellers, retailer, office supply distributors, wireless carriers, catalog and mail order companies, and mass merchants under the Poly, Plantronics, and Polycom brands, as well as RIG sub-brand. Plantronics, Inc. was founded in 1961 and is headquartered in Santa Cruz, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BURTON JOSEPH BCEO - CORPORATE - GLOBAL.E0.Sep 09Option Exercise32.945,000164,700156,960Sep 11 05:42 PM
BURTON JOSEPH BCEO - CORPORATE - GLOBAL.E0.Sep 09Sale33.005,000165,000151,960Sep 11 05:42 PM
LOEBBAKA JEFFTOP SALES EXECUTIVE - GLOBAL.EMay 14Sale44.031,33458,73639,292May 15 06:58 PM
BOYNTON CHARLES DTOP FINANCIAL EXECUTIVE - CFO.May 10Buy42.802,00085,59736,611May 13 09:05 AM
TSEU MARVINDirectorFeb 21Option Exercise36.804,238155,95824,876Feb 22 05:17 PM
CompanyTonix Pharmaceuticals Holding Corp.
Market Cap44.96MEPS (ttm)-8.25
P/E-EPS this Y91.30%
Forward P/E-EPS next Y54.90%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B1.45EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own1.77%Inst Own9.96%
Insider Trans0.00%Inst Trans-
Short Float1.84%EarningsNov 15/a
Analyst Recom2.00Target Price2.90
Avg Volume47.89K52W Range2.69 - 96.00
Nov-04-19 07:00AMTonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya® for PTSD, Following FDA Meeting GlobeNewswire
Oct-31-19 01:00PMTonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split GlobeNewswire
Oct-30-19 03:49PMCompanies Like Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Can Be Considered Quite Risky Simply Wall St.
Oct-23-19 07:54AMThe Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data Benzinga
Oct-23-19 07:00AMTonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX-601 GlobeNewswire
Oct-15-19 07:00AMTonix Pharmaceuticals Joins the Alliance for Biosecurity GlobeNewswire
Oct-07-19 07:00AMTonix Pharmaceuticals Announces that the European Patent Office Opposition Division Has Upheld Its Patent for the Use of the Active Ingredient in TNX-102 SL, Cyclobenzaprine, for the Treatment of PTSD GlobeNewswire
Oct-03-19 08:00AMTonix Pharmaceuticals Announces Completion of Long-Term Exposure Studies in Participants with PTSD to Evaluate the Tolerability of TNX-102 SL 5.6 mg GlobeNewswire
Sep-19-19 09:30AMTNXP: TNX-102 SL P3 PTSD Trial Enrolling; Pipeline Expansion Adds Phase 2 Program and Two Pre-Clinical Programs Zacks Small Cap Research
Sep-17-19 07:23AMThe Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study Benzinga
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease. The company is also developing TNX-601 (tianeptine oxalate) as a daytime administration for the treatment of PTSD and potential indication -neurocognitive dysfunction associated with corticosteroid use that is in pre-investigational new drug (pre-IND) application stage; and TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus, which is in pre-IND application stage. Its product pipeline also includes TNX-701, a biodefense development program for protection from radiation injury. Tonix Pharmaceuticals Holding Corp. has a research collaboration agreement with Massachusetts General Hospital to develop TNX-1500, a humanized monoclonal antibody that targets CD154 for the prevention and treatment of organ transplant rejection. The company was founded in 2007 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEDERMAN SETHChief Executive OfficerMar 29Buy2.495,00012,44032,670Apr 01 08:22 AM
LEDERMAN SETHChief Executive OfficerMar 26Buy2.3825,00059,37527,670Mar 28 05:13 PM
1 2 3 4 5 next